EnGen Bio LLC is a development-stage biotechnology company pioneering a new approach to preventing and treating influenza. The company’s discovery and development stage vaccines (human and veterinary) and human therapeutic antibody target a novel epitope on the flu virus, the M1 matrix protein. This approach is distinct from conventional flu vaccines, which are hemagglutinin- or whole virus–based, and fail to elicit long-lasting and broadly neutralizing antibody responses.

View website: http://www.engenbio.com